We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Mereo Biopharma Group Plc | LSE:MPH | London | Ordinary Share | GB00BZ4G2K23 | ORD GBP0.003 (REG S) |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 26.50 | 26.00 | 27.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMMPH
RNS Number : 7421Z
Mereo BioPharma Group plc
21 May 2019
Mereo BioPharma Group plc
("Mereo" or the "Company")
Notification of Director and other PDMR Dealings
London, May 21, 2019 - Mereo BioPharma Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage UK based biopharmaceutical company focused on rare diseases, on May 20, 2019 granted incentive awards as set out below to persons discharging managerial responsibilities (PDMRs). All the awards were granted for nil consideration and shall ordinarily be forfeit (to the extent unvested) upon cessation of service.
Options to acquire American Depositary Shares ("ADSs") at an exercise price of $5.40 per ADS (Fair Market Value at grant) under the Mereo BioPharma Group plc 2019 Equity Incentive Plan (an employees' share scheme):
Hot Features
Premium
Name of PDMR Position Number of ADSs
over which Option
granted
Denise Scots-Knight Chief Executive Officer 87,500
------------------------------- -------------------
Alastair MacKinnon Chief Medical Officer 27,500
------------------------------- -------------------
Richard Jones Chief Financial Officer 27,500
------------------------------- -------------------
Charles Sermon General Counsel 27,500
------------------------------- -------------------
Head of Patient Access
Wills Hughes-Wilson and Commercial Planning 18,000
------------------------------- -------------------
John Richard Head of Corporate Development 27,500
------------------------------- -------------------
These Options shall normally vest and become exercisable as to one quarter on the first anniversary of their grant date and, thereafter, as to the balance in equal monthly installments over the three-year period following such anniversary.
Awards to either acquire ADSs at an exercise price of $5.40 per ADS (Fair Market Value at grant) or, at the Company's discretion, receive a cash amount equal to the excess, if any, over the exercise price of their Fair Market Value on the exercise date:
Name of PDMR Position Number of ADSs
over which Award
granted
Peter Fellner Chairman 5,500
---------- ------------------
Anders Ekblom Director 5,500
---------- ------------------
Peter Bains Director 5,500
---------- ------------------
Kunal Kashyap Director 5,500
---------- ------------------
Paul Blackburn Director 5,500
---------- ------------------
Deepa Pakianathan Director 5,500
---------- ------------------
Michael Wyzga Director 5,500
---------- ------------------
These awards shall vest in equal monthly installments over the year following their grant date.
The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The forms required under the EU Market Abuse Regulation follow.
1 Details of the person discharging managerial responsibilities
a) Name Denise Scots-Knight
------------------------ ---------------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------------
a) Position/status Chief Executive Officer
------------------------ ---------------------------------------------------
b) Initial notification/ Initial notification
Amendment
------------------------ ---------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------
a) Name Mereo BioPharma Group plc
------------------------ ---------------------------------------------------
b) LEI 213800U8JQHIJOS5AS09
------------------------ ---------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
-----------------------------------------------------------------------------
a) Description of AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING
the financial 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES
instrument, type OF GBP0.003 EACH
of instrument
and identification
code
------------------------ ---------------------------------------------------
b) Nature of the GRANT OF AN OPTION (FOR NO CONSIDERATION)
transaction UNDER THE MEREO BIOPHARMA GROUP PLC 2019
EQUITY INCENTIVE PLAN. THE EXERCISE PRICE
IS US$5.40 PER ADS (FAIR MARKET VALUE AT
GRANT)
------------------------ ---------------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) NIL 87,500
----------
------------------------ ---------------------------------------------------
d) Aggregated information: NOT APPLICABLE - SINGLE TRANSACTION
volume, Price
------------------------ ---------------------------------------------------
e) Date of the transaction May 20, 2019
------------------------ ---------------------------------------------------
f) Place of the Outside of a trading venue
transaction
------------------------ ---------------------------------------------------
1 Details of the person discharging managerial responsibilities
a) Name Alastair MacKinnon
------------------------ ---------------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------------
a) Position/status Chief Medical Officer
------------------------ ---------------------------------------------------
b) Initial notification/ Initial notification
Amendment
------------------------ ---------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------
a) Name Mereo BioPharma Group plc
------------------------ ---------------------------------------------------
b) LEI 213800U8JQHIJOS5AS09
------------------------ ---------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
-----------------------------------------------------------------------------
a) Description of AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING
the financial 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES
instrument, type OF GBP0.003 EACH
of instrument
and identification
code
------------------------ ---------------------------------------------------
b) Nature of the GRANT OF AN OPTION (FOR NO CONSIDERATION)
transaction UNDER THE MEREO BIOPHARMA GROUP PLC 2019
EQUITY INCENTIVE PLAN. THE EXERCISE PRICE
IS US$5.40 PER ADS (FAIR MARKET VALUE AT
GRANT)
------------------------ ---------------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) NIL 27,500
----------
------------------------ ---------------------------------------------------
d) Aggregated information: NOT APPLICABLE - SINGLE TRANSACTION
volume, Price
------------------------ ---------------------------------------------------
e) Date of the transaction May 20, 2019
------------------------ ---------------------------------------------------
f) Place of the Outside of a trading venue
transaction
------------------------ ---------------------------------------------------
1 Details of the person discharging managerial responsibilities
a) Name Richard Jones
------------------------ ---------------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------------
a) Position/status Chief Financial Officer
------------------------ ---------------------------------------------------
b) Initial notification/ Initial notification
Amendment
------------------------ ---------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------
a) Name Mereo BioPharma Group plc
------------------------ ---------------------------------------------------
b) LEI 213800U8JQHIJOS5AS09
------------------------ ---------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
-----------------------------------------------------------------------------
a) Description of AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING
the financial 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES
instrument, type OF GBP0.003 EACH
of instrument
and identification
code
------------------------ ---------------------------------------------------
b) Nature of the GRANT OF AN OPTION (FOR NO CONSIDERATION)
transaction UNDER THE MEREO BIOPHARMA GROUP PLC 2019
EQUITY INCENTIVE PLAN. THE EXERCISE PRICE
IS US$5.40 PER ADS (FAIR MARKET VALUE AT
GRANT)
------------------------ ---------------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) NIL 27,500
----------
------------------------ ---------------------------------------------------
d) Aggregated information: NOT APPLICABLE - SINGLE TRANSACTION
volume, Price
------------------------ ---------------------------------------------------
e) Date of the transaction May 20, 2019
------------------------ ---------------------------------------------------
f) Place of the Outside of a trading venue
transaction
------------------------ ---------------------------------------------------
1 Details of the person discharging managerial responsibilities
a) Name Charles Sermon
------------------------ ---------------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------------
a) Position/status General Counsel
------------------------ ---------------------------------------------------
b) Initial notification/ Initial notification
Amendment
------------------------ ---------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------
a) Name Mereo BioPharma Group plc
------------------------ ---------------------------------------------------
b) LEI 213800U8JQHIJOS5AS09
------------------------ ---------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
-----------------------------------------------------------------------------
a) Description of AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING
the financial 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES
instrument, type OF GBP0.003 EACH
of instrument
and identification
code
------------------------ ---------------------------------------------------
b) Nature of the GRANT OF AN OPTION (FOR NO CONSIDERATION)
transaction UNDER THE MEREO BIOPHARMA GROUP PLC 2019
EQUITY INCENTIVE PLAN. THE EXERCISE PRICE
IS US$5.40 PER ADS (FAIR MARKET VALUE AT
GRANT)
------------------------ ---------------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) NIL 27,500
----------
------------------------ ---------------------------------------------------
d) Aggregated information: NOT APPLICABLE - SINGLE TRANSACTION
volume, Price
------------------------ ---------------------------------------------------
e) Date of the transaction May 20, 2019
------------------------ ---------------------------------------------------
f) Place of the Outside of a trading venue
transaction
------------------------ ---------------------------------------------------
1 Details of the person discharging managerial responsibilities
a) Name Wills Hughes-Wilson
------------------------ ---------------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------------
a) Position/status Head of Patient Access and Commercial Planning
------------------------ ---------------------------------------------------
b) Initial notification/ Initial notification
Amendment
------------------------ ---------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------
a) Name Mereo BioPharma Group plc
------------------------ ---------------------------------------------------
b) LEI 213800U8JQHIJOS5AS09
------------------------ ---------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
-----------------------------------------------------------------------------
a) Description of AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING
the financial 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES
instrument, type OF GBP0.003 EACH
of instrument
and identification
code
------------------------ ---------------------------------------------------
b) Nature of the GRANT OF AN OPTION (FOR NO CONSIDERATION)
transaction UNDER THE MEREO BIOPHARMA GROUP PLC 2019
EQUITY INCENTIVE PLAN. THE EXERCISE PRICE
IS US$5.40 PER ADS (FAIR MARKET VALUE AT
GRANT)
------------------------ ---------------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) NIL 18,000
----------
------------------------ ---------------------------------------------------
d) Aggregated information: NOT APPLICABLE - SINGLE TRANSACTION
volume, Price
------------------------ ---------------------------------------------------
e) Date of the transaction May 20, 2019
------------------------ ---------------------------------------------------
f) Place of the Outside of a trading venue
transaction
------------------------ ---------------------------------------------------
1 Details of the person discharging managerial responsibilities
a) Name John Richard
------------------------ ---------------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------------
a) Position/status Head of Corporate Development
------------------------ ---------------------------------------------------
b) Initial notification/ Initial notification
Amendment
------------------------ ---------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------
a) Name Mereo BioPharma Group plc
------------------------ ---------------------------------------------------
b) LEI 213800U8JQHIJOS5AS09
------------------------ ---------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
-----------------------------------------------------------------------------
a) Description of AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING
the financial 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES
instrument, type OF GBP0.003 EACH
of instrument
and identification
code
------------------------ ---------------------------------------------------
b) Nature of the GRANT OF AN OPTION (FOR NO CONSIDERATION)
transaction UNDER THE MEREO BIOPHARMA GROUP PLC 2019
EQUITY INCENTIVE PLAN. THE EXERCISE PRICE
IS US$5.40 PER ADS (FAIR MARKET VALUE AT
GRANT)
------------------------ ---------------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) NIL 27,500
----------
------------------------ ---------------------------------------------------
d) Aggregated information: NOT APPLICABLE - SINGLE TRANSACTION
volume, Price
------------------------ ---------------------------------------------------
e) Date of the transaction May 20, 2019
------------------------ ---------------------------------------------------
f) Place of the Outside of a trading venue
transaction
------------------------ ---------------------------------------------------
1 Details of the person discharging managerial responsibilities
a) Name Peter Fellner
------------------------ ---------------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------------
a) Position/status Chairman
------------------------ ---------------------------------------------------
b) Initial notification/ Initial notification
Amendment
------------------------ ---------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------
a) Name Mereo BioPharma Group plc
------------------------ ---------------------------------------------------
b) LEI 213800U8JQHIJOS5AS09
------------------------ ---------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
-----------------------------------------------------------------------------
a) Description of AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING
the financial 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES
instrument, type OF GBP0.003 EACH
of instrument
and identification
code
------------------------ ---------------------------------------------------
b) Nature of the GRANT OF AN AWARD (FOR NO CONSIDERATION) UNDER
transaction THE MEREO BIOPHARMA GROUP PLC 2019 NON-EMPLOYEE
EQUITY INCENTIVE PLAN. THE EXERCISE PRICE
IS US$5.40 PER ADS (FAIR MARKET VALUE AT GRANT).
ON EXERCISE, THE COMPANY HAS DISCRETION EITHER
TO DELIVER ADSS OR MAKE A CASH PAYMENT EQUAL
TO ANY EXCESS OF THEIR FAIR MARKET VALUE OVER
THE EXERCISE PRICE
------------------------ ---------------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) NIL 5,500
----------
------------------------ ---------------------------------------------------
d) Aggregated information: NOT APPLICABLE - SINGLE TRANSACTION
volume, Price
------------------------ ---------------------------------------------------
e) Date of the transaction May 20, 2019
------------------------ ---------------------------------------------------
f) Place of the Outside of a trading venue
transaction
------------------------ ---------------------------------------------------
1 Details of the person discharging managerial responsibilities
a) Name Anders Ekblom
------------------------ ---------------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------------
a) Position/status Director
------------------------ ---------------------------------------------------
b) Initial notification/ Initial notification
Amendment
------------------------ ---------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------
a) Name Mereo BioPharma Group plc
------------------------ ---------------------------------------------------
b) LEI 213800U8JQHIJOS5AS09
------------------------ ---------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
-----------------------------------------------------------------------------
a) Description of AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING
the financial 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES
instrument, type OF GBP0.003 EACH
of instrument
and identification
code
------------------------ ---------------------------------------------------
b) Nature of the GRANT OF AN AWARD (FOR NO CONSIDERATION)
transaction UNDER THE MEREO BIOPHARMA GROUP PLC 2019
NON-EMPLOYEE EQUITY INCENTIVE PLAN. THE
EXERCISE PRICE IS US$5.40 PER ADS (FAIR
MARKET VALUE AT GRANT). ON EXERCISE, THE
COMPANY HAS DISCRETION EITHER TO DELIVER
ADSS OR MAKE A CASH PAYMENT EQUAL TO ANY
EXCESS OF THEIR FAIR MARKET VALUE OVER THE
EXERCISE PRICE
------------------------ ---------------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) NIL 5,500
----------
------------------------ ---------------------------------------------------
d) Aggregated information: NOT APPLICABLE - SINGLE TRANSACTION
volume, Price
------------------------ ---------------------------------------------------
e) Date of the transaction May 20, 2019
------------------------ ---------------------------------------------------
f) Place of the Outside of a trading venue
transaction
------------------------ ---------------------------------------------------
1 Details of the person discharging managerial responsibilities
a) Name Peter Bains
------------------------ ---------------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------------
a) Position/status Director
------------------------ ---------------------------------------------------
b) Initial notification/ Initial notification
Amendment
------------------------ ---------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------
a) Name Mereo BioPharma Group plc
------------------------ ---------------------------------------------------
b) LEI 213800U8JQHIJOS5AS09
------------------------ ---------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
-----------------------------------------------------------------------------
a) Description of AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING
the financial 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES
instrument, type OF GBP0.003 EACH
of instrument
and identification
code
------------------------ ---------------------------------------------------
b) Nature of the GRANT OF AN AWARD (FOR NO CONSIDERATION)
transaction UNDER THE MEREO BIOPHARMA GROUP PLC 2019
NON-EMPLOYEE EQUITY INCENTIVE PLAN. THE
EXERCISE PRICE IS US$5.40 PER ADS (FAIR
MARKET VALUE AT GRANT). ON EXERCISE, THE
COMPANY HAS DISCRETION EITHER TO DELIVER
ADSS OR MAKE A CASH PAYMENT EQUAL TO ANY
EXCESS OF THEIR FAIR MARKET VALUE OVER THE
EXERCISE PRICE
------------------------ ---------------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) NIL 5,500
----------
------------------------ ---------------------------------------------------
d) Aggregated information: NOT APPLICABLE - SINGLE TRANSACTION
volume, Price
------------------------ ---------------------------------------------------
e) Date of the transaction May 20, 2019
------------------------ ---------------------------------------------------
f) Place of the Outside of a trading venue
transaction
------------------------ ---------------------------------------------------
1 Details of the person discharging managerial responsibilities
a) Name Kunal Kashyap
------------------------ ---------------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------------
a) Position/status Director
------------------------ ---------------------------------------------------
b) Initial notification/ Initial notification
Amendment
------------------------ ---------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------
a) Name Mereo BioPharma Group plc
------------------------ ---------------------------------------------------
b) LEI 213800U8JQHIJOS5AS09
------------------------ ---------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
-----------------------------------------------------------------------------
a) Description of AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING
the financial 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES
instrument, type OF GBP0.003 EACH
of instrument
and identification
code
------------------------ ---------------------------------------------------
b) Nature of the GRANT OF AN AWARD (FOR NO CONSIDERATION)
transaction UNDER THE MEREO BIOPHARMA GROUP PLC 2019
NON-EMPLOYEE EQUITY INCENTIVE PLAN. THE
EXERCISE PRICE IS US$5.40 PER ADS (FAIR
MARKET VALUE AT GRANT). ON EXERCISE, THE
COMPANY HAS DISCRETION EITHER TO DELIVER
ADSS OR MAKE A CASH PAYMENT EQUAL TO ANY
EXCESS OF THEIR FAIR MARKET VALUE OVER THE
EXERCISE PRICE
------------------------ ---------------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) NIL 5,500
----------
------------------------ ---------------------------------------------------
d) Aggregated information: NOT APPLICABLE - SINGLE TRANSACTION
volume, Price
------------------------ ---------------------------------------------------
e) Date of the transaction May 20, 2019
------------------------ ---------------------------------------------------
f) Place of the Outside of a trading venue
transaction
------------------------ ---------------------------------------------------
1 Details of the person discharging managerial responsibilities
a) Name Paul Blackburn
------------------------ ---------------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------------
a) Position/status Director
------------------------ ---------------------------------------------------
b) Initial notification/ Initial notification
Amendment
------------------------ ---------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------
a) Name Mereo BioPharma Group plc
------------------------ ---------------------------------------------------
b) LEI 213800U8JQHIJOS5AS09
------------------------ ---------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
-----------------------------------------------------------------------------
a) Description of AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING
the financial 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES
instrument, type OF GBP0.003 EACH
of instrument
and identification
code
------------------------ ---------------------------------------------------
b) Nature of the GRANT OF AN AWARD (FOR NO CONSIDERATION)
transaction UNDER THE MEREO BIOPHARMA GROUP PLC 2019
NON-EMPLOYEE EQUITY INCENTIVE PLAN. THE
EXERCISE PRICE IS US$5.40 PER ADS (FAIR
MARKET VALUE AT GRANT). ON EXERCISE, THE
COMPANY HAS DISCRETION EITHER TO DELIVER
ADSS OR MAKE A CASH PAYMENT EQUAL TO ANY
EXCESS OF THEIR FAIR MARKET VALUE OVER THE
EXERCISE PRICE
------------------------ ---------------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) NIL 5,500
----------
------------------------ ---------------------------------------------------
d) Aggregated information: NOT APPLICABLE - SINGLE TRANSACTION
volume, Price
------------------------ ---------------------------------------------------
e) Date of the transaction May 20, 2019
------------------------ ---------------------------------------------------
f) Place of the Outside of a trading venue
transaction
------------------------ ---------------------------------------------------
1 Details of the person discharging managerial responsibilities
a) Name Deepa Pakianathan
------------------------ ---------------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------------
a) Position/status Director
------------------------ ---------------------------------------------------
b) Initial notification/ Initial notification
Amendment
------------------------ ---------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------
a) Name Mereo BioPharma Group plc
------------------------ ---------------------------------------------------
b) LEI 213800U8JQHIJOS5AS09
------------------------ ---------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
-----------------------------------------------------------------------------
a) Description of AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING
the financial 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES
instrument, type OF GBP0.003 EACH
of instrument
and identification
code
------------------------ ---------------------------------------------------
b) Nature of the GRANT OF AN AWARD (FOR NO CONSIDERATION)
transaction UNDER THE MEREO BIOPHARMA GROUP PLC 2019
NON-EMPLOYEE EQUITY INCENTIVE PLAN. THE
EXERCISE PRICE IS US$5.40 PER ADS (FAIR
MARKET VALUE AT GRANT). ON EXERCISE, THE
COMPANY HAS DISCRETION EITHER TO DELIVER
ADSS OR MAKE A CASH PAYMENT EQUAL TO ANY
EXCESS OF THEIR FAIR MARKET VALUE OVER THE
EXERCISE PRICE
------------------------ ---------------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) NIL 5,500
----------
------------------------ ---------------------------------------------------
d) Aggregated information: NOT APPLICABLE - SINGLE TRANSACTION
volume, Price
------------------------ ---------------------------------------------------
e) Date of the transaction May 20, 2019
------------------------ ---------------------------------------------------
f) Place of the Outside of a trading venue
transaction
------------------------ ---------------------------------------------------
1 Details of the person discharging managerial responsibilities
a) Name Michael Wyzga
------------------------ ---------------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------------
a) Position/status Director
------------------------ ---------------------------------------------------
b) Initial notification/ Initial notification
Amendment
------------------------ ---------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------
a) Name Mereo BioPharma Group plc
------------------------ ---------------------------------------------------
b) LEI 213800U8JQHIJOS5AS09
------------------------ ---------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
-----------------------------------------------------------------------------
a) Description of AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING
the financial 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES
instrument, type OF GBP0.003 EACH
of instrument
and identification
code
------------------------ ---------------------------------------------------
b) Nature of the GRANT OF AN AWARD (FOR NO CONSIDERATION)
transaction UNDER THE MEREO BIOPHARMA GROUP PLC 2019
NON-EMPLOYEE EQUITY INCENTIVE PLAN. THE
EXERCISE PRICE IS US$5.40 PER ADS (FAIR
MARKET VALUE AT GRANT). ON EXERCISE, THE
COMPANY HAS DISCRETION EITHER TO DELIVER
ADSS OR MAKE A CASH PAYMENT EQUAL TO ANY
EXCESS OF THEIR FAIR MARKET VALUE OVER THE
EXERCISE PRICE
------------------------ ---------------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) NIL 5,500
----------
------------------------ ---------------------------------------------------
d) Aggregated information: NOT APPLICABLE - SINGLE TRANSACTION
volume, Price
------------------------ ---------------------------------------------------
e) Date of the transaction May 20, 2019
------------------------ ---------------------------------------------------
f) Place of the Outside of a trading venue
transaction
------------------------ ---------------------------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHZFLFLKEFBBBQ
(END) Dow Jones Newswires
May 21, 2019 10:08 ET (14:08 GMT)
1 Year Mereo Biopharma Chart |
1 Month Mereo Biopharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
